Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

Read more about Nektar's technology »

View Nektar's R&D pipeline »

View approved products developed with Nektar technology »

News Contact Investor and Media Inquiries Email: Investors@nektar.com To contact investor and media relations via phone » Business Development and Partnering Email: Partnerships@nektar.com To see the business development team at Nektar » Careers Email: jobs@nektar.com To view and apply to current job opportunities at Nektar »

Partner Spotlight FDA Approval of UCB's Cimzia® for Crohn's Disease Represents Latest Milestone for Nektar Polymer Chemistry Technology Platform Cimzia® is the first and only PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody approved by the FDA. Cimzia® is the ninth marketed product enabled by Nektar's (Nasdaq: NKTR) industry leading PEGylation technology platform. Nektar's partner UCB is also developing Cimzia® in Rheumatoid Arthritis and other autoimmune disease indications. Nektar is proud to support UCB in its development and commercialization of this very important therapeutic. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales of Cimzia® for all indications.